BioCentury
ARTICLE | Financial News

Pacira planning $100 million follow-on

April 8, 2014 1:26 AM UTC

Pain company Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) proposed late Monday to raise $100 million in a follow-on underwritten by Jefferies; Barclays Capital; and BofA Merrill Lynch. Pacira markets Exparel for postoperative pain management in the U.S. The bupivacaine liposome extended-release injectable suspension uses Pacira's DepoFoam drug delivery technology. The company expects 1Q14 net product sales of $34.4 million for Exparel. ...